Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262638 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT01262638: Completed Phase 2 study, sponsored by Esperion Therapeutics.
NCT01262638 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 177 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01262638, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
Primary Outcome
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. Least square (LS) mean percent change from Baseline to Week 12 was based on an analysis of covariance (ANCOVA) model with effects of treatment and triglyceride (TG) stratum and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the last observation carried forwa
Interventions
- DRUG Placebo
- DRUG ETC-1002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-08-23 |
| Phase | Phase 2 |
What the finished NCT01262638 record still lists
NCT01262638 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01262638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01262638 about?
NCT01262638 is a clinical study titled "A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides". This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.
What is the current status of trial NCT01262638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2010-12. Estimated completion is 2011-08-23.
What interventions are being tested in trial NCT01262638?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG).
Who is sponsoring clinical trial NCT01262638?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01262638's enrollment target sits among peer trials
177 394th of 2000 higher than 1,607 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia